160 related articles for article (PubMed ID: 26435191)
1. Functional roles of enhancer of zeste homolog 2 in gliomas.
Yin Y; Qiu S; Peng Y
Gene; 2016 Jan; 576(1 Pt 2):189-94. PubMed ID: 26435191
[TBL] [Abstract][Full Text] [Related]
2. TGF-β-activated lncRNA LINC00115 is a critical regulator of glioma stem-like cell tumorigenicity.
Tang J; Yu B; Li Y; Zhang W; Alvarez AA; Hu B; Cheng SY; Feng H
EMBO Rep; 2019 Dec; 20(12):e48170. PubMed ID: 31599491
[TBL] [Abstract][Full Text] [Related]
3. EZH2 is a potential prognostic predictor of glioma.
Chen YN; Hou SQ; Jiang R; Sun JL; Cheng CD; Qian ZR
J Cell Mol Med; 2021 Jan; 25(2):925-936. PubMed ID: 33277782
[TBL] [Abstract][Full Text] [Related]
4. EZH2 as a potential therapeutic target for gastrointestinal cancers.
Hashemi M; Nazdari N; Gholamiyan G; Paskeh MDA; Jafari AM; Nemati F; Khodaei E; Abyari G; Behdadfar N; Raei B; Raesi R; Nabavi N; Hu P; Rashidi M; Taheriazam A; Entezari M
Pathol Res Pract; 2024 Jan; 253():154988. PubMed ID: 38118215
[TBL] [Abstract][Full Text] [Related]
5. The Cell Cycle: a Key to Unlock EZH2-targeted Therapy Resistance.
Paolini RL; Souroullas GP
Cancer Discov; 2024 Jun; 14(6):903-905. PubMed ID: 38826100
[TBL] [Abstract][Full Text] [Related]
6. Roles of lncRNA-MALAT1 in the Progression and Prognosis of Gliomas.
Ji YL; Kang K; Lv QL; Wang DP
Mini Rev Med Chem; 2024; 24(8):786-792. PubMed ID: 37859309
[TBL] [Abstract][Full Text] [Related]
7. Targeting H3K27me3 loss in pediatric brain tumors - a perspective on epigenetically guided cancer therapy.
Goldstein M
Oncotarget; 2023 May; 14():444-447. PubMed ID: 37171381
[No Abstract] [Full Text] [Related]
8. Targeting glioma stem cells through combined BMI1 and EZH2 inhibition.
Jin X; Kim LJY; Wu Q; Wallace LC; Prager BC; Sanvoranart T; Gimple RC; Wang X; Mack SC; Miller TE; Huang P; Valentim CL; Zhou QG; Barnholtz-Sloan JS; Bao S; Sloan AE; Rich JN
Nat Med; 2017 Nov; 23(11):1352-1361. PubMed ID: 29035367
[TBL] [Abstract][Full Text] [Related]
9. Roles of TRPM channels in glioma.
Chen Z; Xie H; Liu J; Zhao J; Huang R; Xiang Y; Wu H; Tian D; Bian E; Xiong Z
Cancer Biol Ther; 2024 Dec; 25(1):2338955. PubMed ID: 38680092
[TBL] [Abstract][Full Text] [Related]
10. FOSL1's Oncogene Roles in Glioma/Glioma Stem Cells and Tumorigenesis: A Comprehensive Review.
Khedri A; Guo S; Ramar V; Hudson B; Liu M
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791400
[TBL] [Abstract][Full Text] [Related]
11. Current and future therapeutic strategies for high-grade gliomas leveraging the interplay between epigenetic regulators and kinase signaling networks.
Stitzlein LM; Adams JT; Stitzlein EN; Dudley RW; Chandra J
J Exp Clin Cancer Res; 2024 Jan; 43(1):12. PubMed ID: 38183103
[TBL] [Abstract][Full Text] [Related]
12. Protein structuromics: A new method for protein structure-function crosstalk in glioma.
Xiao N; Yang W; Wang J; Li J; Zhao R; Li M; Li C; Liu K; Li Y; Yin C; Chen Z; Li X; Jiang Y
Proteins; 2024 Jan; 92(1):24-36. PubMed ID: 37497743
[TBL] [Abstract][Full Text] [Related]
13. A promising light for an impossible disease: miRNAs in malignant gliomas.
Low YY; Ng WH
CNS Oncol; 2013 Mar; 2(2):107-9. PubMed ID: 25057971
[No Abstract] [Full Text] [Related]
14. Reconstructing the molecular life history of gliomas.
Barthel FP; Wesseling P; Verhaak RGW
Acta Neuropathol; 2018 May; 135(5):649-670. PubMed ID: 29616301
[TBL] [Abstract][Full Text] [Related]
15. Emerging Roles and Mechanisms of RNA Modifications in Neurodegenerative Diseases and Glioma.
Kobayashi A; Kitagawa Y; Nasser A; Wakimoto H; Yamada K; Tanaka S
Cells; 2024 Mar; 13(5):. PubMed ID: 38474421
[TBL] [Abstract][Full Text] [Related]
16. Loss of BAP1 function leads to EZH2-dependent transformation.
LaFave LM; Béguelin W; Koche R; Teater M; Spitzer B; Chramiec A; Papalexi E; Keller MD; Hricik T; Konstantinoff K; Micol JB; Durham B; Knutson SK; Campbell JE; Blum G; Shi X; Doud EH; Krivtsov AV; Chung YR; Khodos I; de Stanchina E; Ouerfelli O; Adusumilli PS; Thomas PM; Kelleher NL; Luo M; Keilhack H; Abdel-Wahab O; Melnick A; Armstrong SA; Levine RL
Nat Med; 2015 Nov; 21(11):1344-9. PubMed ID: 26437366
[TBL] [Abstract][Full Text] [Related]
17. Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2.
Jiao L; Liu X
Science; 2015 Oct; 350(6258):aac4383. PubMed ID: 26472914
[TBL] [Abstract][Full Text] [Related]
18. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.
Perazzoli G; Prados J; Ortiz R; Caba O; Cabeza L; Berdasco M; Gónzalez B; Melguizo C
PLoS One; 2015; 10(10):e0140131. PubMed ID: 26447477
[TBL] [Abstract][Full Text] [Related]
19. Analysis of EZH2: micro-RNA network in low and high grade astrocytic tumors.
Sharma V; Purkait S; Takkar S; Malgulwar PB; Kumar A; Pathak P; Suri V; Sharma MC; Suri A; Kale SS; Kulshreshtha R; Sarkar C
Brain Tumor Pathol; 2016 Apr; 33(2):117-28. PubMed ID: 26746204
[TBL] [Abstract][Full Text] [Related]
20. EZH2 in normal hematopoiesis and hematological malignancies.
Herviou L; Cavalli G; Cartron G; Klein B; Moreaux J
Oncotarget; 2016 Jan; 7(3):2284-96. PubMed ID: 26497210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
